Previous 10 | Next 10 |
home / stock / esalf / esalf news
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050 TOKYO, Feb 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to ...
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives TOKYO, Feb 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been se...
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtaine...
2024-02-13 07:59:24 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen misses top-line and bottom-line estimates; initiates FY...
2024-02-11 01:25:00 ET Summary I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 M. Anbogen Therapeutics raised $12.5M in a Series A funding round. to advance its two lead drug candidates. Bayer signed a non-binding Letter of Intent to m...
2024-02-06 20:49:04 ET Eisai Co Ltd (ESALF) Q3 2023 Results Conference Call February 06, 2024 01:00 AM ET Company Participants Mitsuru Shomon - CFO Keisuke Naito - Global AD Officer Lynn Kramer - Chief Clinical Officer Takashi Owa - Chief Scientific Officer ...
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa TOKYO, Feb 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd ("Eisai South Africa"), a pharmaceuti...
2024-01-30 16:23:19 ET Summary Anti-amyloid drugs likely have little effect on non-APOE4 carriers. Anti-amyloid antibody drugs may have an effect on APOE4 carriers, but with serious and potentially fatal side effects. Safety issues, including potential adverse brain events, ma...
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mec...
2024-01-24 08:54:54 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...